Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Kestra Medical Technologies Ltd (NASDAQ: KMTS) closed at $22.97 up 1.73% from its previous closing price of $22.58. In other words, the price has increased by $1.73 from its previous closing price. On the day, 0.53 million shares were traded. KMTS stock price reached its highest trading level at $23.02 during the session, while it also had its lowest trading level at $21.94.
Ratios:
For a deeper understanding of Kestra Medical Technologies Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.63 and its Current Ratio is at 6.84. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Wolfe Research on March 31, 2025, initiated with a Outperform rating and assigned the stock a target price of $29.
On March 31, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $28.
On March 31, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $28.Stifel initiated its Buy rating on March 31, 2025, with a $28 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 07 ’25 when COHEN RAYMOND W bought 17,000 shares for $17.00 per share. The transaction valued at 289,000 led to the insider holds 29,994 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KMTS now has a Market Capitalization of 1181784704 and an Enterprise Value of 1025159744. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.80 while its Price-to-Book (P/B) ratio in mrq is 6.40. Its current Enterprise Value per Revenue stands at 15.438 whereas that against EBITDA is -9.388.
Stock Price History:
Over the past 52 weeks, KMTS has reached a high of $27.71, while it has fallen to a 52-week low of $13.25. The 50-Day Moving Average of the stock is 14.96%, while the 200-Day Moving Average is calculated to be 12.32%.
Shares Statistics:
For the past three months, KMTS has traded an average of 306.31K shares per day and 228250 over the past ten days. A total of 51.35M shares are outstanding, with a floating share count of 17.17M. Insiders hold about 66.63% of the company’s shares, while institutions hold 32.00% stake in the company. Shares short for KMTS as of 1759190400 were 1958652 with a Short Ratio of 6.39, compared to 1756425600 on 2238414. Therefore, it implies a Short% of Shares Outstanding of 1958652 and a Short% of Float of 8.17.
Earnings Estimates
The dynamic stock of Kestra Medical Technologies Ltd (KMTS) is currently attracting attention from 3 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.55 and low estimates of -$0.59.
Analysts are recommending an EPS of between -$2.15 and -$2.26 for the fiscal current year, implying an average EPS of -$2.19. EPS for the following year is -$1.92, with 3.0 analysts recommending between -$1.83 and -$2.04.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $22.25M. There is a high estimate of $22.7M for the next quarter, whereas the lowest estimate is $22.01M.
A total of 6 analysts have provided revenue estimates for KMTS’s current fiscal year. The highest revenue estimate was $88.6M, while the lowest revenue estimate was $87.82M, resulting in an average revenue estimate of $88.11M. In the same quarter a year ago, actual revenue was $59.81MBased on 6 analysts’ estimates, the company’s revenue will be $130.32M in the next fiscal year. The high estimate is $132M and the low estimate is $129.11M.
